country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-150562

Copy Link Print Information

CDK9-IN-19

CDK9-IN-19 is a highly potent and selective CDK9 inhibitor with an IC₅₀ value of 2.0 nM. CDK9-IN-19 has excellent cellular antiproliferative activity, moderate pharmacokinetic property and low hERG inhibition. CDK9-IN-19 significantly induces tumour growth inhibition in an MV4-11 xenograft mice model. CDK9-IN-19 can be used for researching acute myeloid leukaemia (AML).

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

CAS No.: 2479306-60-8
Formule: C₂₆H₂₂F₂N₄O₅
Masse moléculaire:508.47

Stockage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (274 KB)

CDK9-IN-19 Chemical Structure

CAS No.: 2479306-60-8

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Pureté et documentation
Références
Calculators
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target^[1]

CDK9/cyclinT1

2 nM (IC₅₀)

Voir tous les produits spécifiques à Isoform CDK :

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	IC₅₀	0.09 μM Compound: 30i	Antiproliferative activity against human A-375 cells assessed as inhibition of cell growth incubated for 72 hrs by Celltiter-Glo luminescent assay Antiproliferative activity against human A-375 cells assessed as inhibition of cell growth incubated for 72 hrs by Celltiter-Glo luminescent assay	[PMID: 32447197]
A549	IC₅₀	0.47 μM Compound: 30i	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by Celltiter-Glo luminescent assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by Celltiter-Glo luminescent assay	[PMID: 32447197]
BXPC-3	IC₅₀	0.08 μM Compound: 30i	Antiproliferative activity against human BxPC3 cells assessed as inhibition of cell growth incubated for 72 hrs by Celltiter-Glo luminescent assay Antiproliferative activity against human BxPC3 cells assessed as inhibition of cell growth incubated for 72 hrs by Celltiter-Glo luminescent assay	[PMID: 32447197]
HCT-116	IC₅₀	0.28 μM Compound: 30i	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by Celltiter-Glo luminescent assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by Celltiter-Glo luminescent assay	[PMID: 32447197]
HepG2	IC₅₀	0.1 μM Compound: 30i	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by Celltiter-Glo luminescent assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by Celltiter-Glo luminescent assay	[PMID: 32447197]
MDA-MB-231	IC₅₀	0.23 μM Compound: 30i	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by Celltiter-Glo luminescent assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by Celltiter-Glo luminescent assay	[PMID: 32447197]
MIA PaCa-2	IC₅₀	0.46 μM Compound: 30i	Antiproliferative activity against human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for 72 hrs by Celltiter-Glo luminescent assay Antiproliferative activity against human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for 72 hrs by Celltiter-Glo luminescent assay	[PMID: 32447197]
MOLM-13	IC₅₀	0.26 μM Compound: 30i	Antiproliferative activity against human MOLM-13 cells assessed as inhibition of cell growth incubated for 72 hrs by Celltiter-Glo luminescent assay Antiproliferative activity against human MOLM-13 cells assessed as inhibition of cell growth incubated for 72 hrs by Celltiter-Glo luminescent assay	[PMID: 32447197]
MOLM-13	IC₅₀	0.26 μM Compound: 5	Growth inhibition of human MOLM-13 cells Growth inhibition of human MOLM-13 cells	[PMID: 34415148]
MV4-11	IC₅₀	0.09 μM Compound: 30i	Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth incubated for 72 hrs by Celltiter-Glo luminescent assay Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth incubated for 72 hrs by Celltiter-Glo luminescent assay	[PMID: 32447197]
MV4-11	IC₅₀	0.09 μM Compound: 5	Growth inhibition of human MV4-11 cells incubated after 72 hrs by CTG- luminescence assay Growth inhibition of human MV4-11 cells incubated after 72 hrs by CTG- luminescence assay	[PMID: 34415148]
NCI-H460	IC₅₀	0.64 μM Compound: 30i	Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell growth incubated for 72 hrs by Celltiter-Glo luminescent assay Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell growth incubated for 72 hrs by Celltiter-Glo luminescent assay	[PMID: 32447197]
NCI-N87	IC₅₀	0.6 μM Compound: 30i	Antiproliferative activity against human NCI-N87 cells assessed as inhibition of cell growth incubated for 72 hrs by Celltiter-Glo luminescent assay Antiproliferative activity against human NCI-N87 cells assessed as inhibition of cell growth incubated for 72 hrs by Celltiter-Glo luminescent assay	[PMID: 32447197]
PANC-1	IC₅₀	0.3 μM Compound: 30i	Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell growth incubated for 72 hrs by Celltiter-Glo luminescent assay Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell growth incubated for 72 hrs by Celltiter-Glo luminescent assay	[PMID: 32447197]
SW-620	IC₅₀	0.43 μM Compound: 30i	Antiproliferative activity against human SW-620 cells assessed as inhibition of cell growth incubated for 72 hrs by Celltiter-Glo luminescent assay Antiproliferative activity against human SW-620 cells assessed as inhibition of cell growth incubated for 72 hrs by Celltiter-Glo luminescent assay	[PMID: 32447197]

In Vitro

CDK9-IN-19 (compound 30i) has antiproliferative activity against a panel of human tumor cell lines with IC₅₀ ranks of 0.08~0.64 μM (for example: Hep G2, HCT-116, SW620, A549, MV-4-11, et al.)^[1].
CDK9-IN-19 has low hERG inhibitory activity (IC₅₀=10080 nM) and over 5000-fold selectivity for CDK9^[1].
CDK9-IN-19 (0.1-0.8 μM; 24 h) reduces the expression levels of Mcl-1 and c-Myc^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

MV4-11
Concentration:

0.1, 0.2, 0.4 and 0.8 μM
Incubation Time:

24 h
Result:

Clearly reduced the expression levels of Mcl-1 and c-Myc at 0.1 μM, and completely reduced at 0.2-0.8 μM.

In Vivo

CDK9-IN-19 (10, 20 or 40 mg/kg; IV, for 32 days) significantly suppresses the tumour progression in MV4-11 xenograft model^[1].
Pharmacokinetic Parameters of CDK9-IN-19 in ICR mice^[1].

	PO (30 mg/kg)	IV (2 mg/kg)
T_1/2 (h)	NR	0.23
T_max (h)	0.25	-
C₀ (ng/mL)	-	3060
C_max (ng/mL)	665	-
AUC_0-t (ng/mL·h)	1200	560
AUC_0-∞ (ng/mL·h)	NR	561
CL (L/h/kg)	-	3.56
Vd_SS (L/kg)	-	0.67
F (%)	14.3	-

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female BALB/c nude mice (injected with MV4-11)^[1]
Dosage:

10, 20 or 40 mg/kg
Administration:

IV, for 32 days
Result:

Significantly suppressed the tumour progression and tumour growth inhibition (TGI) values up to 100% from days 14-32 at 40 mg/kg.

Chemical Information

CAS No. 2479306-60-8
Masse moléculaire 508.47
Formule C₂₆H₂₂F₂N₄O₅
SMILES

O=C1C(C(C)=O)=C(N2CCOCC2)C3=C(O1)C=C(NC4=NC=C(F)C(C5=CC=C(F)C=C5OC)=N4)C=C3
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

Please store the product under the recommended conditions in the Certificate of Analysis.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (274 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Xu J, et al. Discovery of coumarin derivatives as potent and selective cyclin-dependent kinase 9 (CDK9) inhibitors with high antitumour activity. Eur J Med Chem. 2020 Aug 15;200:112424. [Content Brief]

Calculators

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

100 mg

Obtenir un devis En stock

Amount: USD 0.00

Activité biologique
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Pureté et documentation
Références

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

CDK9-IN-19

Voir tous les produits spécifiques à Isoform CDK

Activité biologique

Chemical Information

Pureté et documentation

Références

Calculators

Help & FAQs

CDK9-IN-19 Related Classifications

HY-150562 Related Classifications